Multiple Sclerosis Treatment in Germany

Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system that requires lifelong specialist management within a framework that can adapt to the evolving nature of the disease. German university neurology departments operate dedicated MS centres that are recognised within European MS networks and apply current international treatment guidelines with access to the full spectrum of approved disease-modifying therapies. The management of MS in Germany is characterised by a structured approach to diagnosis, disease monitoring, and treatment selection that integrates clinical assessment, high-field MRI, cerebrospinal fluid analysis, and neuropsychological evaluation. For international patients with an established or suspected MS diagnosis, German MS specialists provide independent evaluation of diagnostic accuracy, disease activity status, and the appropriateness of the current treatment strategy — a process that is particularly valuable when treatment escalation, a therapy switch, or management of treatment-related complications is under consideration.

About the Condition

Multiple sclerosis is an immune-mediated condition in which autoreactive T lymphocytes and B cells infiltrate the central nervous system, causing focal areas of demyelination and axonal injury in the brain, spinal cord, and optic nerves. The disease presents in several clinical phenotypes: relapsing-remitting MS (RRMS), which accounts for approximately 85% of initial diagnoses and is characterised by discrete episodes of neurological dysfunction followed by partial or complete recovery; secondary progressive MS (SPMS), which develops in a proportion of RRMS patients and is characterised by gradual neurological deterioration with or without superimposed relapses; and primary progressive MS (PPMS), which presents from onset with progressive disability accumulation without discrete relapses. Diagnosis is established according to the McDonald criteria, which require dissemination of lesions in space and time as demonstrated by clinical findings, MRI, and cerebrospinal fluid analysis. The presence of oligoclonal IgG bands in the CSF supports the diagnosis in clinically uncertain cases.

Common Symptoms

• Optic neuritis — painful unilateral visual loss or blurring, often the presenting feature of MS
• Sensory disturbances including numbness, tingling, or a band-like tightening sensation around the trunk (MS hug)
• Limb weakness or spasticity, typically asymmetric and affecting one or both legs
• Lhermitte's sign — an electric shock sensation radiating down the spine on neck flexion
• Bladder dysfunction including urgency, frequency, incomplete emptying, or urinary incontinence
• Fatigue disproportionate to activity level, often described as the most disabling symptom
• Cognitive impairment affecting processing speed, working memory, and attention
• Heat sensitivity — transient worsening of symptoms in response to elevated body temperature (Uhthoff's phenomenon)
• Cerebellar symptoms including ataxia, dysarthria, and intention tremor

Causes and Risk Factors

Multiple sclerosis arises from a complex interaction between genetic susceptibility and environmental triggers. The strongest genetic association is with HLA-DRB1*15:01, which confers a two- to three-fold increased risk. Other genetic loci identified through genome-wide association studies include genes involved in T cell activation, cytokine signalling, and vitamin D metabolism. Environmental factors with established associations include Epstein-Barr virus infection — particularly infectious mononucleosis in adolescence — low vitamin D levels, cigarette smoking, and obesity in adolescence. Geographic variation in MS prevalence, with higher rates at greater distances from the equator, has historically been attributed to reduced sunlight exposure and vitamin D synthesis, though this relationship is complex and multifactorial. The precise mechanism by which these factors trigger the autoimmune cascade remains an active area of investigation.

Diagnostic Process in Germany

Diagnostic evaluation for MS at German university hospitals begins with high-field MRI of the brain and spinal cord at 3 Tesla, using standardised protocols that include T2-weighted, FLAIR, T1-weighted with and without gadolinium contrast, and diffusion-weighted sequences. MRI findings are assessed for the number, location, and enhancement characteristics of lesions according to the McDonald criteria. Cerebrospinal fluid analysis is performed by lumbar puncture and includes cell count, protein, glucose, IgG index, and isoelectric focusing for oligoclonal bands. Visual evoked potentials assess optic nerve conduction and may provide evidence of subclinical optic nerve involvement. Neuropsychological assessment using validated MS-specific cognitive batteries quantifies cognitive function across multiple domains. Where the diagnosis is uncertain, additional investigations including aquaporin-4 and MOG antibody testing are performed to exclude neuromyelitis optica spectrum disorder and MOG antibody-associated disease, which require different treatment approaches.

Treatment Options in Germany

Treatment of MS at German university hospitals is stratified according to disease phenotype, activity level, disability status, and individual patient factors. For RRMS, treatment is initiated with a disease-modifying therapy selected from the available spectrum, ranging from platform therapies (interferon-beta preparations, glatiramer acetate) and oral agents (dimethyl fumarate, teriflunomide, siponimod, ozanimod, ponesimod) to high-efficacy monoclonal antibodies (natalizumab, ocrelizumab, ofatumumab, alemtuzumab, cladribine). Treatment selection is guided by disease activity, patient preference, risk tolerance, and the presence of prognostic factors indicating a high-risk disease course. For PPMS, ocrelizumab is the only approved disease-modifying therapy and is initiated in eligible patients. Acute relapses are treated with high-dose intravenous methylprednisolone. Symptomatic management addresses spasticity, bladder dysfunction, fatigue, pain, and cognitive impairment through pharmacological and non-pharmacological interventions. Autologous haematopoietic stem cell transplantation (aHSCT) is available at selected German centres for highly active RRMS refractory to conventional disease-modifying therapies.

• High-efficacy disease-modifying therapy: natalizumab, ocrelizumab, ofatumumab, alemtuzumab, cladribine
• Oral disease-modifying agents: dimethyl fumarate, teriflunomide, siponimod, ozanimod
• Platform therapies: interferon-beta-1a, interferon-beta-1b, glatiramer acetate
• Ocrelizumab for primary progressive MS in eligible patients
• Autologous haematopoietic stem cell transplantation (aHSCT) for highly active RRMS at selected centres
• High-dose intravenous methylprednisolone for acute relapse management
• Symptomatic therapy for spasticity (baclofen, tizanidine, botulinum toxin, intrathecal baclofen pump)
• Multidisciplinary neurorehabilitation including physiotherapy, occupational therapy, and cognitive rehabilitation

Why Treatment in Germany

German MS centres are accredited by the German Multiple Sclerosis Society and operate within European MS networks that facilitate access to the latest evidence-based treatment protocols and clinical trial opportunities. High-field MRI at 3 Tesla with standardised acquisition protocols enables sensitive detection of new lesion activity and treatment monitoring. Neuroimmunology specialists at German university hospitals manage complex cases including atypical presentations, treatment-refractory disease, and management of serious adverse events associated with high-efficacy therapies. The integration of MS neurology, neuroradiology, neuropsychology, and neurorehabilitation within a single institutional framework ensures that all aspects of the disease are addressed in a coordinated manner. For patients considering a switch to high-efficacy therapy or aHSCT, German MS specialists provide structured risk-benefit assessment within the context of current evidence.

Specialist Evaluation

An MS specialist evaluation at a German university hospital begins with a comprehensive review of the clinical history, prior MRI studies, CSF results, and current treatment status. The neurologist assesses the accuracy of the MS diagnosis, evaluates for features suggesting an alternative diagnosis such as NMOSD or MOG-AD, and determines the current disease activity status based on clinical relapses and MRI findings. The evaluation addresses whether the current disease-modifying therapy is appropriate for the individual's disease phenotype and activity level, and whether escalation, switch, or continuation is indicated. The evaluation report provides a structured clinical opinion with specific recommendations for further investigation, treatment adjustment, and follow-up monitoring.

Patient Pathway

1. 1

   Submit clinical history, all available MRI studies (brain and spine with and without contrast), CSF results, and current treatment documentation

2. 2

   Clinical coordinator reviews documentation and routes the case to the MS neurology subspecialty team

3. 3

   MS neurologist reviews all available data, assesses diagnostic accuracy and disease activity, and identifies any additional investigations required

4. 4

   Structured evaluation report prepared with diagnostic opinion, disease activity assessment, and treatment recommendations

5. 5

   Case directed to the relevant university hospital MS centre for formal consultation and treatment initiation or adjustment

6. 6

   Ongoing coordination of MRI monitoring, treatment management, and multidisciplinary rehabilitation support

Related Conditions and Services